ZTS - Beat the Dow Jones With This Cash-Gushing Dividend Stock
2024-05-30 08:15:00 ET
Since its spinoff from Pfizer in 2013, animal healthcare behemoth Zoetis (NYSE: ZTS) has seen its cash from operations nearly quintuple as a stand-alone company. Powered by a diverse array of animal health offerings that serve both the companion animal and livestock industries, Zoetis has become a robust, cash-gushing dividend stock.
Its leadership position in a recession-resistant industry has helped the company deliver total returns more than double that of the Dow Jones since 2013. Despite this incredible run, here's the case for why the best may be yet to come for Zoetis, making it a top dividend stock to consider on your quest to beat the Dow.
Zoetis generates 65% of its sales from companion animal products (dogs, pets, and horses) and 34% from its livestock offerings (cattle, swine, poultry, fish, and sheep). Dominant in the animal healthcare industry, Zoetis garners 90% of its sales from species in which it is already a market leader. Similarly, the company holds a No. 1 position in the North American, South American, and Asian markets while also being the second-biggest animal healthcare company in Europe.
For further details see:
Beat the Dow Jones With This Cash-Gushing Dividend Stock